BBVA, which recently went through a rebranding process, selected two Houston startups for its accelerator program. Photo via bbva.com

Two socially minded entrepreneurs in Houston are getting a big boost from a bank-sponsored accelerator program.

The pair of entrepreneurs — leaders of socially focused ventures Eight Million Stories and Small Places LLC — are among 19 social entrepreneurs from across the U.S. chosen to join the BBVA Momentum accelerator program.

This year, BBVA Momentum features five months of online and in-person education lasting from June to November. Headspring Executive Development by Financial Times runs the online component, while the University of Texas at Austin's McCombs School of Business manages the in-person training. Each social entrepreneur is paired with a mentor from banking giant BBVA to provide one-on-one support throughout the program.

At the end of the program, BBVA awards prizes to ventures that have been identified as being highly sustainable and creating the most social impact. Last year's top venture took home $75,000 in equity funding.

Eight Million Stories

One of the two Houston-based startups that was selected for the program is Eight Million Stories, which was founded by Marvin Pierre. The organization helps formerly incarcerated youth (16 to 18 years old) through a free, voluntary four-month program designed to help them:

  • Build strong relationships in their communities.
  • Gain access to an array of social services.
  • Develop life and job skills.
  • Continue their education.
  • Secure meaningful employment.

Pierre says his program "seeks to upend the school-to-prison pipeline by supporting previously incarcerated young people in successfully transitioning back into their communities, and by curbing unnecessary referrals from schools to the juvenile justice system."

Pierre hopes to eventually roll out Eight Million Stories across the country.

"We believe that there are a lot of commonalities in terms of why kids end up in the juvenile justice system, whether it's broken homes or lack of support in the school system or other factors," Pierre says. "If you interview every kid in the system, you'll find there's a common thread. That's what we're trying to undo. If we attack those commonalities, then we can aggressively work to dismantle the school-to-prison pipeline."

Small Places

Finca Tres Robles/Instagram

Today, the main focus of Small Places, co-founded by Daniel Garcia-Prats, is Finca Tres Robles (Spanish for Three Oaks Farm), Houston's only private farm inside the 610 Loop. The farm grows fruits, vegetables, and herbs that are sold to consumers directly by the farm and at local farmers markets.

"Agriculture is fundamentally about people, not plants," Finca Tres Robles says on its website. "While food is central to the work we do, the farm has the capabilities to impact other important areas of health. As an organization, our focus is on developing farms and agricultural spaces that can provide critical health-related services to communities that are need of basic infrastructure to support health."

Among the farm's projects is the Pre-K Produce Program. Finca Tres Robles estimates that thanks to the program, anywhere from $250,000 to $1.25 million in healthcare costs will be saved over the lifetime of the preschoolers.

Small Places also helps run the community farm at the Harris Health System's Lyndon B. Johnson Hospital and operates Houston's 3 Oaks Farms, which focuses on production of the moringa tree, the source of a nutrient-packed superfood.

In a nutshell, Small Places offers:

  • Farm development, management, and consulting services.
  • Education.
  • Community outreach.
  • Job training.

Small Places says it concentrates on "placemaking and community health, helping community- and health-related nonprofits, municipalities that have food security/access issues and progressive commercial developers that want to establish a culture of health in their neighborhoods."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.